Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13895MR)

This product GTTS-WQ13895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1387MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ5451MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ2737MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ1023MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9184MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ9610MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ1649MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ15526MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW